Skip to main content
. 2019 Jan 9;8(1):32. doi: 10.3390/cells8010032

Figure 1.

Figure 1

ADAM 15 is expressed in sera and synovial fluids (SFs). (A) Levels of ADAM15 were higher in RA sera than in normal (NL) sera. (B) The levels of ADAM15 were higher in RA SFs than in osteoarthritis (OA) SFs. (C) Levels of ADAM15 in patients who were treated with tocilizumab. ADAM15 was significantly decreased 24 and 54 weeks after tocilizumab treatment compared with the level prior to treatment. * p < 0.05 was significant.